Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Mondobiotech Holding AG Basel (RLFTF) Message Board

$RLFTF Uncle Gee Gee DD (copy) Some things I pulle

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 653
(Total Views: 365)
Posted On: 10/28/2020 7:24:47 AM
Avatar
Posted By: mc67
$RLFTF Uncle Gee Gee DD (copy) Some things I pulled out of the preprint... pretty amazing.


Important Note: Compared to the control group patients, the Aviptadil patients were coincidentally in significantly worse condition. Their “SOFA score” (which measures organ failure) was significantly worse, and the “Rothman index” (which predicts mortality) was also much worse. Aviptadil patients were already at a disadvantage over the control group, but still managed to produce the following results.

Enrolment

45 patients enrolled - All had the highest possible risk for mortality

21 were selected for Aviptadil in June & July
16 were already on ventilators
5 were already on ventilators and ECMO

24 were selected for the control group in May - Aug
11 were already on ventilators
13 were already on ventilators and ECMO

Results

19 of 21 (90%) Aviptadil patients survived to day 28
4 of 24 (19%) in the control group

4 of 5 (80%) Aviptadil patients on ECMO were removed
3 of 13 (23%) in the control group

15 of 16 (94%) Aviptadil patients on vent were removed
1 of 11 (9%) in the control group

10 Aviptadil patients returned home/care facility
2 in the control group

15 of 21 (71%) Aviptadil patients had 100+ point improvement in oxygenation
4 of 30 (13%) in the control group

Aviptadil Patient Stats
• 9-Fold advantage of survival P<.001
• 9-Fold advantage of recovery from respiratory failure P<.001
• 8 times more likely to return home or a care facility on Aviptadil
• 3-fold improvement in oxygenation
• 17 of 21 saw improvement in both lungs, 2 saw improvement in 1 lung, and 2 showed no improvement
• 2 Patients developed hypotension, which was treated
• 4 Patients developed diarrhea, which was treated


https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3665228


(1)
(0)




Mondobiotech Holding AG Basel (RLFTF) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  


$MJ




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us